Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ODI-2001 |
| Synonyms | |
| Therapy Description |
ODI-2001 is a combination of a neoantigen-expressing DNA vector, a MVA vaccinia virus, and an anti-CTLA4 antibody, which may enhance anti-tumor immune response (J Clin Oncol 42 (16_suppl), e14674). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ODI-2001 | ODI 2001|ODI2001 | ODI-2001 is a combination of a neoantigen-expressing DNA vector, a MVA vaccinia virus, and an anti-CTLA4 antibody, which may enhance anti-tumor immune response (J Clin Oncol 42 (16_suppl), e14674). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07587827 | Phase I | ODI-2001 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer (ODI-2001-01) | Not yet recruiting | FRA | 0 |